Henderson Opportunities Trust — A time to act

Henderson Opportunities Trust (LSE: HOT)

Last close As at 16/01/2025

GBP2.23

6.00 (2.76%)

Market capitalisation

GBP85m

More on this equity

Research: Investment Companies

Henderson Opportunities Trust — A time to act

With a focus on long-term growth, Henderson Opportunities Trust’s (HOT’s) all-market investment strategy includes a strong bias towards smaller and earlier-stage companies. The relative weakness of smaller companies in the past three years, particularly AIM stocks, has weighed heavily on HOT’s performance, obscuring its previous exceptional returns. It is in this context that HOT is one of the trusts targeted by the activist US hedge fund Saba Capital, which is proposing to oust the independent board and replace the trust’s investment managers. HOT’s board strongly urges shareholders to reject Saba’s proposals on their own merits. Only if this occurs will shareholders be able to consider the board’s own proposals for HOT, which, in our view, are significantly more attractive. These include a full cash exit at NAV and/or the option to roll over into an alternative, open-ended vehicle.

Martyn King

Written by

Martyn King

Director, Financials

Investment companies

UK all-cap equities

17 January 2025

Price 223.00p
Market cap £87m
Total assets £99m
NAV 234.2
Discount to NAV 0.5%
Current yield 3.3%
Shares in issue 39.5m
Code/ISIN HOT/GB00BSHRGN41
Primary exchange LSE
AIC sector UK All Companies
52-week high/low 239.0p 182.2p

Fund objective

Henderson Opportunities Trust aims to achieve capital growth in excess of the broad UK stock market from a portfolio of UK investments. Stock selection is not constrained by the benchmark and there are no limits by sector or market capitalisation. Therefore, the portfolio will differ materially from the index.

Bull points

  • Opportunities across all market segments and market capitalisation.
  • Disciplined approach to stock selection, valuation and portfolio diversification.
  • Experienced and stable management team with consistent long-term strategy

Bear points

  • High portfolio weighting in smaller and earlier-stage companies, where liquidity can be thin and returns can be volatile.
  • Investor appetite for UK smaller companies remains subdued.
  • Relatively small size means HOT could be overlooked by some investors.

Analyst

Martyn King
+44 (0)20 3077 5700

Henderson Opportunities Trust is a research client of Edison Investment Research Limited

When investor confidence is low, the share prices of smaller and mid-sized companies, as well as growth stocks, are often weaker compared with large global stocks. Over the past three years, this trend has been particularly pronounced, especially for domestically focused businesses, and is reflected in HOT’s performance, even over 10 years. This is despite HOT generating a c 100% NAV total return to the first seven years, double that of its broad market benchmark, and ahead of the Numis Smaller Companies Index including AIM and excluding investment trusts (NSCIAEX), which is more representative of HOT’s investment strategy. This strategy has been clearly articulated and consistently applied over many years by two experienced fund managers, James Henderson and Laura Foll of Janus Henderson. Frustratingly for investors, when the asset class is out of favour, the discount to NAV remains stubbornly wide. Historical performance shows that when sentiment turns, discount narrowing significantly enhances shareholder returns. The fund managers are positive about the prospects for the UK equity market and highlight that valuations remain highly attractive on both an absolute and relative basis, particularly for smaller companies.

Saba has beneficial interest in HOT of c 28%. It is proposing to remove the independent board of HOT (and those of six other trusts) and replace it, at least initially, with just two individuals nominated by Saba, one of whom is a Saba partner. We believe this raises important governance issues, particularly as Saba intends the existing management contracts to be terminated and has ambitions to be appointed as investment manager. While the details remain unclear, it appears that, across the seven trusts targeted by Saba, it will, in many cases, seek a significant change in investment mandates, merging the trusts into a new sector consolidations fund. Saba says that it will offer a ‘substantial’ liquidity event to shareholders wanting to exit HOT, but this appears to be on a partial basis, in contrast to the full cash alternative proposed by the HOT board.

The Saba proposals will be voted on by shareholders in a general meeting requisitioned for 4 February 2025, although the deadline for casting proxy votes through investor platforms will be earlier. The circular can be found here, as well as information on how to vote. HOT’s board strongly recommends that shareholders vote against the Saba proposals, and we agree. The proposals put forward by the HOT board are contingent on this being the case. In addition to the full cash exit option, the alternative investment roll-over option into the Janus Henderson UK Equity & Income Growth Fund provides an opportunity for investors to maintain their UK equity exposure and may benefit some in managing capital gains tax liabilities.

NOT INTENDED FOR PERSONS IN THE EEA

True to its strategy and HOT’s board has acted decisively

Our previous research covering HOT’s strategy, performance, investment process and portfolio positioning can be found here. We have also published in detail and from a sector context on the Saba campaign here. Investor activism may be beneficial for the shareholders of investment trusts as it encourages the trusts’ boards to intensify their efforts to maximise shareholder total returns and shareholder dialogue. However, we believe that Saba’s intention to use the targeted trusts as a platform to build a UK discount arbitrage franchise goes beyond pure investor activism. Saba presents a biased narrative to achieve its objectives and its recent proposals lack the necessary details to make an informed decision to vote in favour of them. This includes details related to:

  1. The significant, immediate liquidity events (eg tender offers and/or buybacks) at NAV to be offered to shareholders, including Saba’s approach to the less liquid public small-cap and private holdings of these trusts;
  2. The new investment mandate of buying/merging with discounted trusts and the plan for transitioning the trusts’ portfolio; and
  3. Measures to protect the rights of other shareholders, most notably the process for appointing new independent board members beyond the directors proposed in Saba’s open letter.

HOT has consistently provided an investment strategy that is complementary to a wider range of more mainstream offerings, seeking to provide long-term growth, mainly from smaller companies, while balancing the risks through a high level of stock diversification (c 90 holdings) and meaningful exposure to larger, more established businesses. For many investors, this would be difficult to replicate and HOT’s permanent capital base is ideally suited to the long-term, patient approach required. The challenging market conditions for smaller companies since late 2021 have been notable for both their duration and extent. While past recoveries have shown that this can quickly change, the timing of a significant turning point remains elusive.

Having traded at close to NAV, as smaller stocks rose strongly in absolute and relative terms coming out of the COVID-19 pandemic lockdowns, the shares have, until recently, traded at a 15–20% discount as investor enthusiasm for smaller stocks waned. It is the steady acquisition of shares by Saba that has closed the discount in recent months. In this context of weak performance and the persistent discount, and pre-dating the Saba proposals, the board had already instructed advisers to commence work on putting forward a scheme of reconstruction, giving all shareholders the choice between ongoing investment in an open-ended investment company managed by Janus Henderson Investors and an unlimited cash exit at NAV. Contingent on the Saba proposals being rejected, shareholders will be able to vote on whether the company reconstruction should proceed and, assuming it is approved, they will have the choice between cash or roll-over or some mix of both.

Recent underperformance masks a longer period of success

Given its strategic focus on smaller companies, HOT’s performance has always showed significant divergence from that of its benchmark over shorter periods. In our view, we believe the NSCIAEX to be more reflective of the trust’s clearly expressed and consistently applied strategy. A comparison of performance versus the broad market benchmark is a measure of the long-term success of the strategy. Smaller companies performed strongly coming out of the COVID-19 pandemic lockdowns but this has been followed by three years of underperformance, notable for both its duration and extent, especially for those listed on AIM.

In 2021, HOT’s investment managers took advantage of rising smaller company share prices to shift the balance of the portfolio towards larger, more-established companies. With the benefit of hindsight, they could have done more but argue against materially doing so now. Smaller company underperformance over the past three years has had a significantly negative impact on HOT’s performance track record, obscuring the exceptionally strong performance in the previous period. Over the three years to 31 October 2024 (FY24), HOT’s NAV total return of -21.8% compares very poorly with the 19.7% benchmark return and this feeds through to all other periods up to 10 years.

Looking at the HOT performance data on a discrete calendar year basis highlights that HOT’s underperformance stems from the period since FY22 and particularly that year. Somewhat distorted by market volatility during the COVID-19 pandemic, HOT has tended to outperform the index when the market is rising. In FY22, although the broad market fell only modestly, positive performance by the largest 20 companies (almost 60% of total market cap) was offset by strong declines across the wider market and especially AIM.

Looking more closely at the past 10 years of annual data, during the first seven years, HOT’s NAV total return of 100% was more than twice the 50% delivered by its benchmark. Smaller companies outperformed during the period but HOT’s performance still exceeded the NSCIAEX return of 91%.

Over the more recent three-year period, HOT’s NAV total return has materially underperformed its broad market benchmark, driven primarily by small-cap weakness, particularly among AIM-listed companies.

Over the past year, the NSCIAEX has slightly outperformed the broad UK market and so too as HOT, even though AIM has continued to lag significantly, but it is too early to call a turning point. The month-on-month pattern is volatile and smaller companies are typically more sensitive to the UK economy, where growth forecasts have begun to moderate.

The roll-over proposal

The roll-over fund proposed by the board, the Janus Henderson UK Equity & Income Growth Fund, is an open-ended investment company rather than an investment trust like HOT, but it nonetheless provides a significant degree of continuity for HOT investors. Like HOT, it is managed by Foll and Henderson and invests primarily in UK companies selected from across the market, ranging from small-cap and AIM-listed stocks to the very largest companies. It follows a similar bottom-up investment process, with a strong valuation discipline and an often contrarian stance. However, its primary objective is income, which results in a larger weighting to large-cap stocks than HOT (c 70% in the top 100 companies, compared with c 35% for HOT) and a higher portfolio yield. The Janus Henderson UK Equity & Income Growth Fund focuses on companies trading at a valuation discount to peers and/or their historical averages, which the managers believe is unjustified and where there is a clear path to a re-rating. For this reason, its portfolio trades at a valuation discount to the broader UK market. At the end of December, the portfolio was trading at c 9.5x forward earnings. The 31 December factsheet shows a trailing yield for the fund of 4.0%, compared with HOT’s yield of 3.3%.

General disclaimer and copyright

This report has been commissioned by Henderson Opportunities Trust and prepared and issued by Edison, in consideration of a fee payable by Henderson Opportunities Trust. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Henderson Opportunities Trust

View All

Latest from the Investment Companies sector

View All Investment Companies content

Research: Healthcare

Newron Pharmaceuticals — Spotlight on evenamide following licensing deals

We refresh our valuation for Newron Pharmaceuticals in light of the licensing agreements for its lead asset, evenamide, in Japan and South Korea. The €117m deal with EA Pharma in Japan (c 10% of evenamide’s global market) was particularly significant, with an upfront payment of €44m and committed trial cost contributions (estimated at c €10m) securing Newron’s cash runway into H226. This de-risks the 12-month Phase III trial plan, set to commence in H125. Furthermore, South Korean partner Myung In Pharm will contribute 10% of the Phase III patient population and related costs as part of undisclosed licensing terms. Evenamide is a first-in-class therapy being developed for treatment-resistant schizophrenia (TRS), with its potential backed by favourable Phase II/III data. As we update our estimates to reflect these developments, our valuation increases to CHF18.5 per share (from CHF12.3/share previously).

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free